GlassScriptPhysician profile
Jessie Correa
NPI 1093202889
$12,336.03
in general payments reported to CMS, 2019-2025
36 companies · $741 in 2025
The $741 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,672 · 2022: $3,091 · 2023: $1,821 · 2024: $3,011 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,417 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,417.13 |
| Education | $155.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,844.86 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,129.46 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,422.56 | 2021-2025 | Stelara, Tremfya, Remicade |
| Intercept Pharmaceuticals, INC. | $901.41 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $608.70 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $593.28 | 2021-2025 | |
| Redhill Biopharma INC. | $577.17 | 2021-2024 | Aemcolo, Talicia, Movantik |
| Ardelyx, INC. | $464.56 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $363.43 | 2021-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $297.41 | 2021-2024 | Stelara |
| Aimmune Therapeutics, INC. | $295.78 | 2024 | |
| Nestle Healthcare Nutrition INC. | $254.08 | 2021-2023 | |
| Celgene Corporation | $230.48 | 2021-2024 | Zeposia |
| Vivus LLC | $163.49 | 2021-2023 | Qsymia |
| Ipsen Biopharmaceuticals, INC | $144.72 | 2023-2024 | Iqirvo, Bylvay |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $139.36 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $111.52 | 2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $89.23 | 2021-2022 | |
| Lilly USA, LLC | $82.37 | 2023-2024 | Omvoh |
| Daiichi Sankyo INC. | $79.36 | 2021-2022 | |
| Madrigal Pharmaceuticals | $71.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $66.66 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $61.07 | 2021-2024 | Linzess |
| Evoke Pharma, INC. | $53.48 | 2021-2024 | Gimoti |
| Braintree Laboratories, INC. | $44.85 | 2021-2024 | Sutab |
| Novo Nordisk INC | $38.06 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $35.76 | 2022-2024 | Dificid |
| Alnylam Pharmaceuticals INC. | $29.33 | 2022 | |
| Pfizer INC. | $27.15 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.72 | 2022 | |
| Exact Sciences Corporation | $18.38 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $16.71 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.23 | 2024 | Zeposia |
| Alfasigma USA, INC. | $15.99 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.42 | 2024 | Terlivaz |
| Ethicon US, LLC | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessie Correa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.